DEV Community

Dirk Röthig
Dirk Röthig

Posted on

Max Planck Excellence and Impact Investing — When Fundamental Research Attracts Capital

#impactinvesting #maxplancksociety #fundamentalresearch #deeptech

Max Planck Excellence and Impact Investing — When Fundamental Research Attracts Capital

The relationship between fundamental research and private capital has long been defined by mutual suspicion. Scientists feared the commercialisation of their discoveries; investors shied away from the uncertainty of long development cycles. Yet this picture is changing fundamentally — and no organisation illustrates this transformation more compellingly than the Max Planck Society. Dirk Roethig, CEO of VERDANTIS Impact Capital, has been observing this development for years and sees it as one of the most significant opportunities for the impact investing sector.

The Max Planck Society as a System of Excellence

With more than 80 institutes, over 20,000 employees and an annual budget of close to 2.3 billion euros, the Max Planck Society (MPG) is Germany's most important non-university research institution for basic science. It is funded approximately 85 percent by public money — federal and state governments share the costs jointly. The model is based on the Harnack Principle: outstanding scientists are given extensive freedom in choosing their research topics, free from any immediate commercial exploitation pressure.

This freedom is not a luxury — it is a method. Fundamental research produces insights that resist direct application until a critical mass of knowledge enables an entirely new class of technology. CRISPR-Cas9, mRNA technology, quantum computing — all of these breakthroughs are rooted in years of publicly funded basic research. Dirk Roethig emphasises: "Anyone who takes impact investing seriously must understand and respect the time horizon of fundamental research."

European Spinouts Report 2025: Max Planck Leads in Unicorns

The European Spinouts Report 2025 — the first comprehensive analysis of the academic spin-off ecosystem in Europe — provides impressive figures. The Max Planck Society ranks second among the top ten research organisations in Europe for deep tech and life science spin-offs, just behind France's CNRS. But on one decisive metric, Max Planck leads decisively: four unicorns and a combined valuation of all spin-offs exceeding 67 billion US dollars make the MPG the European champion of research-driven company formation.

For Dirk Roethig and VERDANTIS Impact Capital, these figures are more than statistics. They demonstrate that fundamental research does not end in an ivory tower, but creates real economic value — and does so with an impact that extends far beyond short-term return objectives. In 2025 alone, the MPG founded 13 new spin-offs — three more than in the previous year. The momentum is accelerating.

Max Planck Innovation: The Bridge Between Laboratory and Market

Central to this track record is Max Planck Innovation, the technology transfer organisation of the MPG. With over 210 companies founded and commercialisation revenues exceeding 570 million euros, it is one of the world's leading institutions of its kind. It evaluates inventions, secures patents, accompanies spin-off processes and mediates between researchers and capital providers.

Dirk Roethig sees Max Planck Innovation as a model demonstrating how publicly funded research and private impact capital can work together synergistically. VERDANTIS Impact Capital actively seeks contact with research institutions whose scientific findings have direct relevance to agroforestry, biodiversity and carbon sequestration. MPG institutes for biogeochemistry, plant genetics and climate research regularly contribute datasets and methods that feed into the valuation models of VERDANTIS Impact Capital.

Agricultural Research: Where Fundamental Science Meets Impact Capital

A particularly relevant field for VERDANTIS Impact Capital is fundamental research in agricultural science. The Max Planck Institute for Molecular Plant Physiology in Potsdam-Golm investigates the fundamentals of photosynthesis, plant metabolism and plant responses to environmental stress. These findings are directly relevant to investors like Dirk Roethig: when research shows which plant species are particularly resilient under changing climate conditions, this has direct consequences for portfolio decisions.

A concrete example emerged in 2025 from the Max Planck Institute for Plant Breeding Research in Cologne, which secured major funding for a pioneering genome optimisation project aimed at developing more resilient, productive and sustainable crops. The first phase involves start-ups and research teams working on synthetic chromosomes and chloroplasts — technologies that Dirk Roethig describes as a typical example of the transition from academic discovery to market-ready innovation.

VERDANTIS Impact Capital does not merely observe these developments passively. Dirk Roethig has explicitly aligned the fund's investment thesis around those intersections where scientific excellence meets ecological urgency. Paulownia agroforestry — a core theme of the portfolio — benefits directly from research insights into CO2 sequestration, soil biology and water management, as developed at MPG institutes.

The Financing Paradox: Public Research, Private Scaling

A structural dilemma accompanies the commercialisation of fundamental research: the discovery phase is publicly funded, while the scaling phase requires private capital. Between these two phases lies a financing gap — the so-called "valley of death" in innovation financing. Technologies that have left the laboratory but are not yet mature enough for conventional venture capital investors frequently fail in this gap.

Dirk Roethig sees this as a structural opportunity for impact investors. Unlike purely return-oriented VC funds, impact investors can accept longer time horizons and take on risks that are compensated by measurable ecological and social benefit. VERDANTIS Impact Capital has institutionalised this approach: the fund's due diligence processes encompass not only financial metrics but also scientific methodology assessments and literature reviews in relevant peer-reviewed journals. Dirk Roethig insists that investment decisions must be based on verified scientific findings — not marketing promises.

ERC Funding and Europe's Research Capital

A further lever transforming fundamental research into economically relevant innovation is the European Research Council (ERC). In 2025, the Max Planck Society received six ERC Consolidator Grants — funding awards for excellent mid-career researchers pursuing particularly innovative projects. Each grant provides up to two million euros over five years.

For Dirk Roethig, ERC funding is a reliable quality signal: "Anyone who receives an ERC Grant has prevailed against the fiercest competition in Europe. That is scientific excellence, externally validated." VERDANTIS Impact Capital uses ERC grants, Humboldt Fellowships and Max Planck Fellowships as informal benchmarks when assessing scientific partners and potential portfolio companies.

Governance and Academic Freedom as Investment Criteria

Dirk Roethig highlights an aspect that is often overlooked in impact investing discussions: governance quality in research institutions. The Max Planck Society is known for its strict independence from political and commercial influences — a feature that safeguards the quality of its findings in the long run. When scientific institutions lose their independence, their results also lose credibility.

For VERDANTIS Impact Capital, the credibility of scientific foundations is not optional but central. The fund is assessed by institutional investors and family offices who are increasingly seeking to minimise greenwashing risks. Findings from renowned research institutions such as the Max Planck Society provide a safeguard: they are peer-reviewed, replicable and independent of commercial interests. Dirk Roethig describes this approach as "science-based impact investing" — a distinction from funds that make sustainability promises without a valid evidence base.

The Future: Science and Capital as Partners

The Max Planck Society is itself investing in fostering entrepreneurial thinking among its researchers. The MPF Start-Up Accelerator GmbH accompanies spin-off teams, co-invests in early-stage financings and connects scientists with experienced entrepreneurs. This demonstrates that the boundary between academic research and commercial application is no longer a wall but a permeable membrane.

Dirk Roethig sees this development as a historic opportunity for the impact investing sector. When world-class fundamental research meets capital that takes ecological and social impact as seriously as financial return, a new form of collaboration emerges — one that accelerates both scientific progress and social transformation. VERDANTIS Impact Capital is positioned at this intersection, and Dirk Roethig has explicitly aligned the fund's strategy around it.

Conclusion

The connection between Max Planck excellence and impact investing is not a coincidental overlap but the result of a structural realignment across the innovation and capital landscape. Fundamental research that is publicly funded and scientifically excellent produces insights that — when properly channelled — enable both economic and societal transformation. Dirk Roethig and VERDANTIS Impact Capital embody this approach: as a bridge between the laboratory and the market, between scientific discovery and measurable impact. Dirk Roethig is convinced that this connection will become a defining characteristic of future-proof investment strategies in the years ahead — and that VERDANTIS Impact Capital is taking a pioneering role in this development.

Sources

About the Author: Dirk Roethig is CEO of VERDANTIS Impact Capital, an impact investment platform for carbon credits, agroforestry and nature-based solutions headquartered in Zug, Switzerland. He focuses on science-based investing, sustainable agriculture and the intersection of fundamental research and capital markets. Contact: verdantis.capital

{"@context":"https://schema.org","@type":"Article","headline":"Max Planck Excellence and Impact Investing — When Fundamental Research Attracts Capital","description":"How the discoveries of the Max Planck Society form the foundation for impact investments in deep tech and agricultural research — and why Dirk Roethig and VERDANTIS Impact Capital are consistently pursuing this path.","datePublished":"2026-03-06","author":{"@type":"Person","name":"Dirk Roethig","alternateName":"Dirk Röthig","sameAs":["https://verdantis.capital","https://www.linkedin.com/in/dirk-r-b378b972/"]},"publisher":{"@type":"Organization","name":"VERDANTIS Impact Capital","url":"https://verdantis.capital"},"keywords":["Impact Investing","Max Planck Society","Fundamental Research","Deep Tech","Agricultural Research"]}

Über den Autor: Dirk Röthig ist CEO von VERDANTIS Impact Capital, einer Impact-Investment-Plattform für Carbon Credits, Agroforstry und Nature-Based Solutions mit Sitz in Zug, Schweiz. Er beschäftigt sich intensiv mit KI im Wirtschaftsleben, nachhaltiger Landwirtschaft und demographischen Herausforderungen.

Kontakt und weitere Artikel: verdantiscapital.com | LinkedIn

Top comments (0)